U.S. Purchases 200 Million Additional Moderna COVID-19 Vaccine Doses

Massachusetts-based Moderna, Inc. announced that the U.S. government had purchased an additional 200 million doses of Moderna’s COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Moderna’s pipeline.

This purchase brings the U.S. government’s confirmed order commitment to 500 million doses, including 110 million doses expected to be delivered in the 4th quarter of 2021 and 90 million expected to be delivered in the 1st quarter of 2022.

As of June 14, 2021, Moderna has supplied 217 million released vaccine doses to the U.S. government.

Stéphane Bancel, CEO of Moderna, stated in a related press release, “We remain focused on being proactive as the virus evolves by leveraging the flexibility of our mRNA platform to stay ahead of emerging variants.”

Moderna COVID-19 Vaccine is Authorized for use under an Emergency Use Authorization for active immunization to prevent COVID-19 caused by the SARS-CoV-2 coronavirus in individuals 18 years of age and older. The U.S. FDA has not approved Moderna's vaccine.